Bridge Biotherapeutics, Inc.

A288330

KR7288330004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
2,220 ^KRW	+1.60%		-3.48%	-32.42%

03-28	Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	CI
03-26	Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	CI

Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding

January 21, 2024

On January 22, 2024, Bridge Biotherapeutics, Inc. closed the transaction.

Latest news about Bridge Biotherapeutics, Inc.

Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade	03-28	CI
Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology	03-26	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding	01-21	CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 1.99999872 billion in funding	01-11	CI
Gpcr Therapeutics, Inc. Collaborates with Bridge Biotherapeutics, Inc. to Pursue Joint Development and Commercialization of the Combination Therapy	12-14	CI
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC	30/10/23	CI
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis	26/10/23	CI
Bridge Biotherapeutics, Inc.(KOSDAQ:A288330) dropped from S&P Global BMI Index	18/09/23	CI
Bridge Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Bridge Biotherapeutics Inc. Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting	18/04/23	CI
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis	12/04/23	CI
Bridge Biotherapeutics Presents Phase 2A Clinical Trial Results for BBT-401	20/02/23	CI
Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis	07/11/22	CI
Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022	02/09/22	CI
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877	16/08/22	CI
Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022	10/08/22	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 2.99997 billion in funding from a group of investors	29/06/22	CI
Bridge Biotherapeutics to Sell Shares to Raise $38 Million	24/05/22	MT
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 48.59976 billion in funding from a group of investors	21/05/22	CI
Bridge Biotherapeutics, Inc. Presents Preclinical Data of BBT-207 at the AACR Annual Meeting 2022	12/04/22	CI
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics	07/02/22	CI
Bridge Biotherapeutics, Inc. Announces Initiation of the Phase I Clinical Trial for BBT-401 in China	19/10/21	CI
Bridge Biotherapeutics Presents Pre-Clinical Data of BBT-176 at the European Society for Medical Oncology Virtual Congress 2021	16/09/21	CI
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis	13/06/21	CI
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for Bbt-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site	01/06/21	CI

Chart Bridge Biotherapeutics, Inc.

Duration

Period

More charts

Bridge Biotherapeutics, Inc. is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The products mainly consist of ulcerative colitis medicine BBT-401, autoxin inhibitor BBT-877, non-small cell lung cancer medicine BBT-176, and others. The Company is also involved in the manufacture of basic pharmaceuticals and biologicals.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BRIDGE BIOTHERAPEUTICS, INC.	-32.42%	39.55M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs

Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

Biotechnology & Medical Research

Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding

Latest news about Bridge Biotherapeutics, Inc.

Chart Bridge Biotherapeutics, Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs